Transcription factor E2F5 (E2F5) (E2F5)

Transcription factor E2F5 is a member of the E2F family of proteins that play a crucial role in the control of the cell cycle and the action of tumor suppressor proteins [1]. Unlike the activating E2Fs (E2F1-3), E2F5 is traditionally classified as a transcriptional repressor that binds to pocket proteins like p130 (RBL2) to maintain cells in a quiescent G0/G1 state [1, 2]. However, in various malignancies, E2F5 is frequently overexpressed and functions as an oncogene, promoting cell proliferation, migration, and invasion by regulating the expression of genes involved in the G1/S transition [3, 4]. It is particularly noted for its role in ovarian cancer, where it serves as a potential diagnostic and prognostic marker and is often found to be amplified [3]. Therapeutic strategies focusing on E2F5 mRNA involve the use of microRNAs (miRNAs) or small interfering RNAs (siRNAs) to silence its expression, thereby inhibiting tumor growth and sensitizing cells to chemotherapy [4, 5]. Experimental evidence suggests that downregulating E2F5 can induce apoptosis and cell cycle arrest in multiple cancer types, including breast and hepatocellular carcinoma [4, 5]. Despite its potential, targeting E2F5 remains a challenge due to the high homology between E2F family members and the necessity of E2F function in normal tissue homeostasis [1, 2].

Other names

E2F-5Transcription factor E2F5E2F5_HUMAN

Downregulation of E2F5 expression through RNA interference or antisense oligonucleotides to inhibit tumor cell proliferation and induce apoptosis.